Noticeably, the PI3K/AKT signaling pathway is commonly found to be hyper-activated in HCC, and inhibiting this pathway is one of the critical therapeutic approaches to treating HCC [34]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.